Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Simultaneous Inhibition of cIAP1, cIAP2 and XIAP Is Required for Inducing Apoptosis in Multiple Myeloma Cells.

Vijay G. Ramakrishnan, PhD, Teresa K. Kimlinger, Utkarsh Painuly, MD, Jessica Haug, S. Vincent Rajkumar, MD, Shaji K. Kumar, MD

Blood (2012) 120 (21): 2943.

https://doi.org/10.1182/blood.V120.21.2943.2943

Published: 2012

Journal Articles

Preclinical Evaluation of AT219, a Small Molecule Inhibitor of MDM2 As an Anti-Myeloma Agent.

Vijay G. Ramakrishnan, PhD, Teresa K. Kimlinger, Timothy Halling, Jessica Haug, Utkarsh Painuly, MD, S. Vincent Rajkumar, MD, Shaji K. Kumar, MD

Blood (2012) 120 (21): 2948.

https://doi.org/10.1182/blood.V120.21.2948.2948

Published: 2012

Journal Articles

Investigational Agent MLN2238/MLN9708, a Specific, Orally Available, Small Molecule Proteasome Inhibitor, Shows Promising In Vitro Activity Against Multiple Myeloma Cell Lines

Giada Bianchi, MD, Vijay G. Ramakrishnan, PhD, Teresa Kimlinger, Jessica Haug, S. Vincent Rajkumar, MD, Shaji Kumar, MD

Blood (2010) 116 (21): 3014.

https://doi.org/10.1182/blood.V116.21.3014.3014

Published: 2010

Journal Articles

Significant In Vitro Activity of a Novel Inhibitor of Apoptosis (IAP) Inhibitor LC161 In Multiple Myeloma

Jessica Haug, Vijay G. Ramakrishnan, PhD, Teresa Kimlinger, Timothy Halling, Linda Wellik, S. Vincent Rajkumar, MD, Shaji Kumar, MD

Blood (2010) 116 (21): 2998.

https://doi.org/10.1182/blood.V116.21.2998.2998

Published: 2010

Journal Articles

Mechanism of Action of a Novel c-Met Inhibitor MK2461 In Multiple Myeloma

Vijay G. Ramakrishnan, PhD, Teresa Kimlinger, Jessica Haug, Timothy Halling, Linda Wellik, S. Vincent Rajkumar, MD, Shaji Kumar, MD

Blood (2010) 116 (21): 4078.

https://doi.org/10.1182/blood.V116.21.4078.4078

Published: 2010

Journal Articles

Significant in-Vitro Activity of a Novel JAK2 Inhibitor in Multiple Myeloma Associated with Preferential Cytotoxicity for CD45+ Myeloma Cells.

Vijay Ramakrishnan, PhD, Jessica Haug, Teresa Kimlinger, Timothy Halling, Linda Wellik, Animesh D. Pardanani, MBBS, PhD, Ayalew Tefferi, MD, S. Vincent Rajkumar, MD, Shaji Kumar, MD

Blood (2009) 114 (22): 2848.

https://doi.org/10.1182/blood.V114.22.2848.2848

Published: 2009

Journal Articles

Thymoglobulin (Polyclonal Rabbit Anti Thymocyte Globulin) Has In Vivo Activity in a Mouse Model of Myeloma.

Michael Timm, Linda Wellik, Teresa Kimlinger, Jessica Haug, Michael Kline, Ph.D, S. Vincent Rajkumar, MD, Philip Greipp, MD, Shaji Kumar, MD

Blood (2006) 108 (11): 3487.

https://doi.org/10.1182/blood.V108.11.3487.3487

Published: 2006

Journal Articles

Gene Expression Profiling of Myeloma Cells at Diagnosis Can Predict Response to Therapy with Thalidomide and Dexamethasone Combination.

Shaji Kumar, MD, Philip R. Greipp, MD, Jessica Haug, MD, Michael Kline, PhD, Wee Joo Chng, Emily Blood, MS, Leif Bergsagel, MD, John A. Lust, MD, Morie A. Gertz, MD, Rafael Fonseca, MD, S. Vincent Rajkumar, MD

Blood (2005) 106 (11): 508.

https://doi.org/10.1182/blood.V106.11.508.508

Published: 2005

Journal Articles

Identification of Genes Associated with Increased Bone Marrow Angiogenesis in Multiple Myeloma.

Michael Kline, PhD, S. Vincent Rajkumar, MD, Jessica Haug, Linda Wellik, John A. Lust, MD, PhD, Rafael Fonseca, MD, Philip R. Greipp, MD, Shaji Kumar, MD

Blood (2005) 106 (11): 5109.

https://doi.org/10.1182/blood.V106.11.5109.5109

Published: 2005

Journal Articles

Comparison of Myeloma Cell Gene Expression Profiles Pre and Post Thalidomide - Dexamethasone Therapy Provides Insight into Potential Mechanisms.

Shaji Kumar, MD, Philip R. Greipp, MD, Jessica Haug, Michael Kline, PhD, Emily Blood, MS, Wee Joo Chng, John A. Lust, MD, Leif Bergsagel, MD, Morie A. Gertz, MD, Rafael Fonseca, MD, S. Vincent Rajkumar, MD

Blood (2005) 106 (11): 3480.

https://doi.org/10.1182/blood.V106.11.3480.3480

Published: 2005

Journal Articles

AT-101, a Small Molecule Inhibitor of Bcl-2 Family Proteins, Has Significant In Vitro Activity in Multiple Myeloma.

Shaji Kumar, MD, Michael Kline, PhD, Terry Kimlinger, BA, Michael Timm, Jessica Haug, Philip R. Greipp, MD, Dajun Yang, MD, PhD, S. Vincent Rajkumar, MD

Blood (2005) 106 (11): 1581.

https://doi.org/10.1182/blood.V106.11.1581.1581

Published: 2005

Journal Articles

ABT-737, an Inhibitor of Bcl-2/Bcl-X L Proteins, Is Cytotoxic in Multiple Myeloma Cells.

Michael Kline, PhD, Terry Kimlinger, Michael Timm, Jessica Haug, John A. Lust, MD, PhD, S.Vincent Rajkumar, MD, Shaji Kumar

Blood (2005) 106 (11): 1589.

https://doi.org/10.1182/blood.V106.11.1589.1589

Published: 2005

Journal Articles

Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression

Shaji Kumar, Thomas E. Witzig, Michael Timm, Jessica Haug, Linda Wellik, Teresa K. Kimlinger, Philip R. Greipp, S. Vincent Rajkumar

Blood (2004) 104 (4): 1159–1165.

https://doi.org/10.1182/blood-2003-11-3811

Published: 2004

NARROW

Simultaneous Inhibition of cIAP1, cIAP2 and XIAP Is Required for Inducing Apoptosis in Multiple Myeloma Cells.

Preclinical Evaluation of AT219, a Small Molecule Inhibitor of MDM2 As an Anti-Myeloma Agent.

Investigational Agent MLN2238/MLN9708, a Specific, Orally Available, Small Molecule Proteasome Inhibitor, Shows Promising In Vitro Activity Against Multiple Myeloma Cell Lines

Significant In Vitro Activity of a Novel Inhibitor of Apoptosis (IAP) Inhibitor LC161 In Multiple Myeloma

Mechanism of Action of a Novel c-Met Inhibitor MK2461 In Multiple Myeloma

Significant in-Vitro Activity of a Novel JAK2 Inhibitor in Multiple Myeloma Associated with Preferential Cytotoxicity for CD45+ Myeloma Cells.

Thymoglobulin (Polyclonal Rabbit Anti Thymocyte Globulin) Has In Vivo Activity in a Mouse Model of Myeloma.

Gene Expression Profiling of Myeloma Cells at Diagnosis Can Predict Response to Therapy with Thalidomide and Dexamethasone Combination.

Identification of Genes Associated with Increased Bone Marrow Angiogenesis in Multiple Myeloma.

Comparison of Myeloma Cell Gene Expression Profiles Pre and Post Thalidomide - Dexamethasone Therapy Provides Insight into Potential Mechanisms.

AT-101, a Small Molecule Inhibitor of Bcl-2 Family Proteins, Has Significant In Vitro Activity in Multiple Myeloma.

ABT-737, an Inhibitor of Bcl-2/Bcl-X L Proteins, Is Cytotoxic in Multiple Myeloma Cells.

Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only